Fabry disease is a lysosomal storage disorder (LSD) caused by deficiency of
α-galactosidase A (α-gal A), resulting in deposition of
globotriaosylceramide (Gb3; also known as ceramide trihexoside) in the vascular
endothelium of many organs. A gradual accumulation of Gb3 leads to cardiovascular,
cerebrovascular and renal dysfunction. Endothelial cell dysfunction leads to renal
complications, one of the main symptoms of Fabry disease. However, the pathological
mechanisms by which endothelial dysfunction occurs in Fabry disease are poorly
characterized. The purpose of this study was to investigate whether the expression of
transforming growth factor-β1 (TGF-β1) and vascular endothelial growth
factor (VEGF) is associated with the renal pathogenesis of Fabry disease. We found that
the protein expression levels of renal thrombospondin-1 (TSP-1), TGF-β1 and VEGF
were higher in the kidneys from Fabry mice compared to wild-type mice. The expression
levels of VEGF receptor 2 (VEGFR2), fibroblast growth factor-2 (FGF-2) and phospho-p38
(P-p38) were also higher in the kidneys from Fabry mice compared with wild-type mice.
Activities of cysteine aspartic acid protease (caspase)-6 and caspase-9 were higher in
kidneys from Fabry than from the wild-type mice. These results suggest that overexpression
of TGF-β1 and VEGF in the Fabry mouse kidney might contribute to Fabry disease
nephropathy by inducing apoptosis. To test whether Gb3 accumulation can induce apoptosis,
we incubated bovine aortic endothelial cells with Gb3 and found increased expression of
TGF-β1, VEGFR2, VEGF, FGF-2 and P-p38. The combination of increased expression of
TGF-β1 and VEGF caused by Gb3 accumulation may allow upregulation of FGF-2, VEGFR2
and P-p38 expression, and these changes may be associated with Fabry disease nephropathy
by inducing apoptosis.
Fabry disease is a lysosomal storage disorder caused by deficiency of alpha-galactosidase A (α-gal A), which results in the deposition of globotriaosylceramide (Gb3) in the vascular endothelium. Globotriaosylsphingosine (lyso-Gb3), a deacylated Gb3, is also increased in the plasma of patients with Fabry disease. Renal fibrosis is a key feature of advanced Fabry disease patients. Therefore, we evaluated the association of Gb3 and lyso-Gb3 accumulation and the epithelial–mesenchymal transition (EMT) on tubular epithelial cells of the kidney. In HK2 cells, exogenous treatments of Gb3 and lyso-Gb3 increased the expression of TGF-β, EMT markers (N-cadherin and α-SMA), and phosphorylation of PI3K/AKT, and decreased the expression of E-cadherin. Lyso-Gb3, rather than Gb3, strongly induced EMT in HK2 cells. In the mouse renal mesangial cell line, SV40 MES 13 cells, Gb3 strongly induced phenotype changes. The EMT induced by Gb3 was inhibited by enzyme α-gal A treatment, but EMT induced by lyso-Gb3 was not abrogated by enzyme treatment. However, TGF-β receptor inhibitor (TRI, SB525334) inhibited the activation of TGF-β and EMT markers in HK2 cells with Gb3 and lyso-Gb3 treatments. This study suggested that increased plasma lyso-Gb3 has a crucial role in the development of renal fibrosis through the cell-specific induction of the EMT in Fabry disease, and that TRI treatment, alongside enzyme replacement therapy, could be a potential therapeutic option for patients with Fabry disease.
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding the α-galactosidase A (α-Gal A) lysosomal enzyme, which results in globotriaosylceramide (Gb3) storage in vascular endothelial cells and different cell types throughout the body. Involvement of the of Fabry disease. An increased concentration of deacylated Gb3 (lyso-Gb3) in the plasma of symptomatic patients has also been suggested as a causative molecular event. To elucidate the molecular mechanisms involved in renal fibrosis in Fabry disease, the present analyzed the changes in global gene expression prior to and following Gb3 or lyso-Gb3 treatment in two types of kidney cell lines, human proximal renal tubular epithelial (HK-2) and mouse renal glomerular mesangial (SV40 MES 13) cells. Gb3 and lyso-Gb3 treatment regulated the expression of 199 and 328 genes in each cell type, demonstrating a >2.0-fold change. The majority of the biological functions of the regulated genes were associated with fibrogenesis or epithelial-mesenchymal transition (EMT). The gene expression patterns of sphingolipid-treated HK-2 cells were distinguishable from the patterns in the SV40 MES 13 cells. Several genes associated with the EMT were selected and evaluated further in kidney cells and in Fabry mouse kidney tissues. In the SV40 MES 13 cells, the DLL1, F8, and HOXA11 genes were downregulated, and FOXP2 was upregulated by treatment with Gb3 or lyso-Gb3. In the HK-2 cells, the ADAMTS6, BEST1, IL4, and MYH11 genes were upregulated. Upregulation of the FOXP2, COL15A1, IL4, and MYH11 genes was also observed in the Fabry mouse kidney tissues. The gene expression profiles in kidney cells following the addition of Gb3 or lyso-Gb3 revealed substrate-specific and cell-specific patterns. These findings suggested that Gb3 and lyso-Gb3 lead to renal fibrosis in Fabry disease through different biochemical modulations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.